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Purpose: One of the greatest challenges currently facing those
studying Mendelian disease is identifying the pathogenic variant
from the long list produced by a next-generation sequencing test.
We investigate the predictive ability of homozygosity mapping for
identifying the regions likely to contain the causative variant.
Methods:We use 179 homozygous pathogenic variants from three
independent cohorts to investigate the predictive power of
homozygosity mapping.
Results: We demonstrate that homozygous pathogenic variants in
our cohorts are disproportionately likely to be found within one of
the largest regions of homozygosity: 80% of pathogenic variants are
found in a homozygous region that is in the ten largest regions in a
sample. The maximal predictive power is achieved in patients with
<8% homozygosity and variants >3Mb from a telomere; this gives
an area under the curve (AUC) of 0.735 and results in 92% of the
causative variants being in one of the ten largest homozygous
regions.
Conclusion: This predictive power can be used to prioritize the list
of candidate variants in gene discovery studies. When classifying a
homozygous variant the size and rank of the region of
homozygosity in which the candidate variant is located can also
be considered as supporting evidence for pathogenicity.
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INTRODUCTION
The advent of high-throughput next-generation sequencing
has been a boon to the study of Mendelian disease. It is now
possible to screen thousands of genes in a single test.
However, this generates an extensive list of variants. One of
the greatest challenges currently facing those studying
Mendelian disease is identifying the pathogenic variant
amongst the myriad of other variants.1 To help with this
task the American College of Medical Genetics and Genomics
(ACMG) has developed guidelines2 for variant interpretation,
providing a process for classifying variants using all different
types of potential available evidence.
Searching for shared regions of homozygosity between
affected individuals has been used to identify genes causing
recessive Mendelian diseases.3 Identifying target genes within
shared regions of homozygosity is a critical step in
consanguineous families with recessive disorders.4 Regions
of homozygosity are created when identical-by-descent
haplotypes are inherited from parents. A homozygosity map
can be generated directly from next-generation sequencing
data, identifying regions likely to contain the causative
variant.5
The number and size of homozygous regions within an
individual’s genome is influenced by ancestral population
effects and recent consanguineous events. It is important to
differentiate the two cases as disease-causing variants are
likely to be in regions of recent homozygosity; variants in
ancestral regions of homozygosity have been exposed to
selection in a homozygous state for sufficient time for
selection to act on them. Ancestral regions of homozygosity
are likely to be smaller, less than a megabase, whereas
homozygous regions that are the result of recent consangui-
nity tend to be multiple megabases in length.6 Thus we would
expect variants that cause recessive Mendelian disease to be
contained in the largest regions of homozygosity.
To test the hypothesis that homozygous pathogenic variants
are more likely to be found in the largest regions of
homozygosity in a sample, we used a data set of 99
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consanguineous patients with previously identified homo-
zygous pathogenic variants. We then replicated our findings
in two further cohorts, with 17 and 63 patients respectively.
MATERIALS AND METHODS
Cohort descriptions
Our discovery cohort consisted of patients referred to the
molecular genetics department at the Royal Devon and Exeter
Hospital for genetic testing for neonatal diabetes (NDM) or
hyperinsulinemic hypoglycemia (HH). Samples were
sequenced on a targeted gene panel test for monogenic
diabetes and HH.9 99 consanguineous patients were diag-
nosed as having a homozygous pathogenic variant.
We replicated our findings in two further cohorts: first,
consanguineous patients with severe pediatric disorders where
exome sequencing identified 17 homozygous pathogenic
variants; and second, 63 consanguineous children from the
Deciphering Developmental Disorders (DDD) study7,8 with a
pathogenic or likely pathogenic homozygous variant identi-
fied using trio exome sequencing and shared via
DECIPHER.10
Patients were defined as consanguineous if more than 1.5%
of their genome was covered by homozygous regions >3Mb.
This is the expected percentage of homozygosity for offspring
of second cousin marriages.11 Levels of homozygosity were
similar between cohorts: discovery cohort mean 8.7% (SD
4.5%), severe pediatric disorders cohort 8.8% (6.6%), DDD
cohort 9.2% (4.5%).
Informed consent was obtained at referral. See Supplemen-
tary Information for details on consent and statistics.
Homozygosity mapping
For our discovery cohort, regions of homozygosity were
detected directly from the targeted sequencing data using
SavvyHomozygosity, which uses off-target reads.12,13 For the
two replication cohorts, regions of homozygosity were
calculated from VCF files using SavvyVcfHomozygosity.12,13
The pathogenic variants in our samples were discovered
independently of the regions of homozygosity mapping; they
were not used to guide variant discovery.
RESULTS
79% of pathogenic variants are found in a homozygous
region that is in the ten largest regions
In our discovery cohort we found that the largest regions of
homozygosity in each sample were more likely to contain the
pathogenic variant. In fact, the rank (receiver operator
characteristic [ROC] area under the curve [AUC] 0.666), size
(AUC 0.627), and relative size (size of homozygous region
divided by size of the largest region in the sample) (AUC
0.668) all have predictive power (Supplementary Figure 1A).
79% of pathogenic variants are found in the ten largest
homozygous regions in a sample. 87% of pathogenic variants
are found in a homozygous region >5Mb. 84% of pathogenic
variants are found in a homozygous region no more than five
times smaller than the largest region. The mean size of the
homozygous regions in our samples is 18.9 Mb (SD 15.1 Mb)
while 89.7% of homozygous regions are >5Mb. The predictive
ability of the combined metrics is greater than any individual
measure (AUC 0.684).
The largest regions have predictive value over and above
the proportion of homozygosity they account for
Figure 1 and Supplementary Figure 2 demonstrate that the
causative variant is disproportionately likely to be in a large
region, over and above the proportion of homozygous bases
the region accounts for. For example, in our discovery cohort
79% of pathogenic variants are in the ten largest regions but
these only account for 55% of homozygous bases. The number
of pathogenic variants in the 50% of bases accounted for by
the largest regions of homozygosity is significantly higher
than the number of pathogenic variants in the 50% of bases
from the smallest regions (P= 5.5 × 10-5). We have sufficient
power to detect this effect: a minimum of 51 samples is
required to detect the proportion with 80% power and P=
0.05. This pattern is demonstrated by the ROC curve in
Supplementary Figure 1A.
Homozygous region rank and size have predictive power in
replication cohorts
We replicated our findings in two independent cohorts. The
rank, size, and relative size of the homozygous regions all have
predictive power in both replication cohorts (Supplementary
Figures 1B and 1C). When we combine all three data sets the
AUC is 0.630 for rank, 0.613 for size, 0.643 for relative size,
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Figure 1 Rank, size, and relative size have predictive power. The
receiver operator characteristic (ROC) curve for our combined data set
(discovery cohort plus replication cohorts, excluding samples with homo-
zygosity >8% and variants within 3Mb of a telomere) demonstrates that
there is positive predictive value for each of rank, size, and relative size, with
the highest predictive value coming when these are combined
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and 0.654 combining all three metrics (Supplementary
Figure 1D). In the combined data set 80% of pathogenic
variants are found in the ten largest regions.
Excluding samples with homozygosity >8% and variants
within 3 Mb of a telomere improves predictive power
We investigated the characteristics of those samples where the
causative variant was not in one of the ten largest regions:
these had a higher amount of homozygosity (mean 11.9 vs.
8.3%). Additionally genes near telomeres were more likely to
have causative variants that were not in the ten largest regions
(eight variants within 3Mb of a telomere, only one in the ten
largest regions, P= 0.000055, Fisher's exact test). If we only
include samples with <8% homozygosity and exclude variants
within 3 Mb of a telomere the AUC increases to 0.735 and
92% of causative variants are in one of the ten largest
homozygous regions (Figure 2).
Using rank and relative size of the homozygous region to
guide variant interpretation
Using rank alone to evaluate pathogenicity has predictive
power, but using multiple metrics improves on this.
Supplementary Table 1 provides a homozygosity rank (HR)
score for homozygous regions based on the rank and relative
size of our combined data set (excluding samples with
homozygosity >8% and variants within 3Mb of a telomere).
The HR score is the percentage of bases in homozygous
regions that are smaller than the one under consideration.
Ninety-two percent of causative variants are in a homozygous
region with a HR score of 42 or more; this threshold can be
used in the routine assessment of novel variants.
DISCUSSION
Presence of a variant in a large region of homozygosity has
predictive power
We demonstrate in our discovery cohort that the rank, size,
and relative size of homozygous regions have predictive power
for whether a variant is causative. We replicated this pattern
in two independent cohorts.
We would expect the causative variant to be in the largest
regions of homozygosity because these have been formed by
recent consanguineous events.6 Smaller regions are present in
the population from ancestral events and have thus been in
the population for longer; this means they have been exposed
to selection pressures for longer, thus are less likely to contain
disease-causing variants. We expect to see enrichment of
pathogenic variants in the largest homozygous regions in all
recessive Mendelian disorders where the disease is severe
enough to strongly affect reproductive fitness.
Presence of a variant in one of the ten largest regions of
homozygosity is supporting evidence for pathogenicity
The ACMG guidelines2 incorporate different types of
evidence into the overall classification: population frequency
data, in silico predictions, functional data, and cosegregation
of the variant with the disease within the family. We have
demonstrated that a variant being within a large homozygous
region has predictive power as to the pathogenicity of the
variant. The data used by this test is uncorrelated with other
predictors of pathogenicity so can be used in combination.
We therefore suggest that the presence of a homozygous
variant in one of the ten largest regions of homozygosity
could to be used as supporting evidence in the context of
variant classification using the ACMG guidelines.
Limitations
The samples for this study are from multiple global
populations, which could be a confounding factor as different
populations are known to have different patterns of homo-
zygosity.6 We also observed that in samples with greater levels
of homozygosity predictive power was reduced. However,
there is predictive power even in samples with very high
(>8%) levels of homozygosity and we suggest that the
biological principle should be generally applicable across
individuals and populations—that the causative homozygous
variant will tend to be in a larger homozygous region, because
these are the result of recent consanguineous events. This
metric should be applicable for all consanguineous patients—
consanguinity (homozygosity >1.5%) can be determined from
sequencing data and does not need to be known a priori.
The predictive power of homozygous regions should be
agnostic to the method used to call the regions; however,
certain areas of the genome are harder to sequence and thus
contain more false heterozygous variants, which have the
potential to artificially break up large regions of homozygos-
ity. This can be reduced by using only variants that are in
Hardy–Weinberg equilibrium and allowing some heterozy-
gous variants within homozygous regions.
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Figure 2 The largest regions of homozygosity contain more patho-
genic variants than would be expected from the proportion of
homozygous bases the regions account for. Results shown for our
combined data set (discovery cohort plus replication cohorts), excluding
samples with homozygosity >8% and variants within 3Mb of a telomere.
The solid bars represent the cumulative proportion of homozygous patho-
genic variants that are within regions of that rank or larger while the hollow
bars represent the cumulative number of bases within homozygous regions
of that rank or larger. AUC is the area under the curve
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We observed that causative variants close to telomeres were
less likely to be within the ten largest regions of homozygosity.
We hypothesize that proximity to the end of the chromosome
restricts the size of the homozygous region; this is an
application of the inspection paradox14 (Supplementary
Information). Thus we caution against using this metric to
exclude variants within 3Mb of a telomere.
This test only provides supporting evidence for
pathogenicity
Within our data set, some of the pathogenic variants were not
present in a large homozygous region; this is likely caused by
small community effects and founder mutations, as well as the
effect of proximity to a telomere. It is therefore important to
remember that the presence of a variant outside of a large
homozygous region does not prove it is benign just as the
presence of a variant in one of the largest regions of
homozygosity does not provide conclusive evidence of patho-
genicity. It does however provide additional complementary
evidence with a similar predictive power (overall AUC 0.654
rising to 0.735 excluding samples with homozygosity >8% and
variants within 3Mb of a telomere) to widely used tools such as
SIFT (AUC 0.631–0.848) and PolyPhen (AUC 0.596–0.859)15.
Homozygosity mapping guides gene discovery
We can apply our results to prioritize the list of candidate
variants in gene discovery studies. For example, 80% of
pathogenic variants are found in a homozygous region that is
in the ten largest regions but only 61% of homozygous bases
fulfill the same criteria. Using such a prioritization enriches
the remaining regions for pathogenic variants. This is of
particular value for gene discovery within consanguineous
cohorts without multiple affected members in a single family
to narrow down target regions.
Conclusion
In conclusion, the size, rank, and relative size of the
homozygous region a variant is found in provides evidence
of its likely pathogenicity. 92 percent of pathogenic variants
are found in the ten largest regions of homozygosity
(excluding samples >8% homozygosity and variants within
3Mb of a telomere). We suggest this criterion could be used
in the context of the ACMG guidelines as a potential source of
supporting evidence for variant pathogenicity.
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